Kintor Pharmaceutical (HKG:9939) posted positive interim results from a long-term human safety trial of KT-939 and has begun the registration process for the compound as a new cosmetic ingredient in China, according to a Wednesday Hong Kong bourse filing.
The company said 119 participants received continuous topical treatment with KT-939 for 28 weeks, with no adverse skin reactions reported.
The trial is evaluating the safety of a cosmetic formulation containing 0.2% KT-939 over 52 consecutive weeks and is expected to be completed in September.